|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:academic_advisor
|
renowned.
|
|
gptkbp:acquired_by
|
gptkb:Roche
|
|
gptkbp:acquisition
|
gptkb:Roche
|
|
gptkbp:acquisition_year
|
gptkb:2019
|
|
gptkbp:advocacy
|
supportive
|
|
gptkbp:awards
|
various industry awards
|
|
gptkbp:biotechnology_advancements
|
leveraging.
|
|
gptkbp:ceo
|
gptkb:Jeffrey_D._Marrazzo
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:Canada
gptkb:United_States
ongoing
diverse population
Phase 3
ongoing.
gene therapy for beta-thalassemia
gene therapy for sickle cell disease
gene therapy for Alzheimer's disease
gene therapy for Parkinson's disease
gene therapy for cystic fibrosis
gene therapy for multiple sclerosis
gene therapy for spinal muscular atrophy
published.
robust.
promising results.
gene therapy for hemophilia
aiming for.
gene therapy for amyotrophic lateral sclerosis (ALS)
gene therapy for Duchenne muscular dystrophy
gene therapy for hemophilia A
gene therapy for hemophilia B
gene therapy for inherited retinal diseases
gene therapy for muscular dystrophy
|
|
gptkbp:collaboration
|
gptkb:Bristol-Myers_Squibb
gptkb:University_of_Pennsylvania
pursuing.
|
|
gptkbp:collaborations
|
gptkb:Penn_Medicine
academic institutions
various institutions
|
|
gptkbp:community_engagement
|
active
|
|
gptkbp:community_support
|
active involvement.
|
|
gptkbp:employees
|
over 200
|
|
gptkbp:financial_performance
|
growing revenue
|
|
gptkbp:financial_support
|
available.
|
|
gptkbp:focus
|
gptkb:gene_therapy
|
|
gptkbp:focus_area
|
gptkb:Fuchsia
gptkb:muscular_dystrophy
gptkb:neurodegenerative_diseases
metabolic disorders
central nervous system disorders
ophthalmology
|
|
gptkbp:focuses_on
|
gptkb:gene_therapy
|
|
gptkbp:founded
|
gptkb:2013
|
|
gptkbp:founder
|
gptkb:Jeffrey_D._Marrazzo
|
|
gptkbp:funding
|
secured.
|
|
gptkbp:future_goals
|
clear.
|
|
gptkbp:future_plans
|
expand pipeline.
|
|
gptkbp:gene_therapy_advancements
|
leading.
|
|
gptkbp:has_advisory_board
|
established
|
|
gptkbp:head_of_state
|
active.
|
|
gptkbp:headquarters
|
gptkb:Philadelphia,_Pennsylvania
|
|
gptkbp:healthcare
|
improving.
driving.
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Spark Therapeutics
|
|
gptkbp:initiatives
|
diverse.
|
|
gptkbp:innovation
|
key focus.
|
|
gptkbp:instruction_set
|
multiple gene therapies
|
|
gptkbp:invention
|
strong portfolio
|
|
gptkbp:investment
|
$1.5 billion
Venture capital firms
transparent.
|
|
gptkbp:is_a_platform_for
|
advanced.
|
|
gptkbp:market
|
conducted.
|
|
gptkbp:market_cap
|
approximately $1 billion
|
|
gptkbp:market_position
|
global
|
|
gptkbp:marketing_strategy
|
focused.
|
|
gptkbp:mission
|
transform lives through gene therapy.
|
|
gptkbp:notable_investments
|
gptkb:New_Enterprise_Associates
gptkb:Sofinnova_Partners
gptkb:Foresite_Capital
gptkb:Canaan_Partners
gptkb:Orbi_Med_Advisors
|
|
gptkbp:notable_products
|
gptkb:Luxturna
|
|
gptkbp:partnership
|
gptkb:Astellas_Pharma
gptkb:Novartis
biopharmaceutical companies
|
|
gptkbp:partnerships
|
forming.
exploring.
|
|
gptkbp:patient_centric_approach
|
emphasized.
|
|
gptkbp:patient_education
|
important.
|
|
gptkbp:product_type
|
gene therapy products
|
|
gptkbp:public_company
|
gptkb:true
|
|
gptkbp:publications
|
numerous.
|
|
gptkbp:regulatory_compliance
|
ongoing.
strict.
multiple submissions
FDA approval for Luxturna
|
|
gptkbp:research
|
ongoing.
|
|
gptkbp:research_and_development
|
significant investment
|
|
gptkbp:research_areas
|
retinal diseases
expanding.
|
|
gptkbp:research_focus
|
rare genetic diseases
|
|
gptkbp:research_institutes
|
gptkb:Children's_Hospital_of_Philadelphia
|
|
gptkbp:side_effect
|
significant.
|
|
gptkbp:social_responsibility
|
committed.
|
|
gptkbp:stakeholders
|
proactive.
|
|
gptkbp:stock_symbol
|
gptkb:ONCE
|
|
gptkbp:strategic_goals
|
expand gene therapy applications.
|
|
gptkbp:team
|
experienced.
|
|
gptkbp:technology_platform
|
AAV vector technology
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:treatment
|
improved
|
|
gptkbp:type_of
|
gptkb:public_company
|
|
gptkbp:vision
|
a world where genetic diseases are treated.
|
|
gptkbp:website
|
www.sparktx.com
|
|
gptkbp:bfsParent
|
gptkb:Roche
|
|
gptkbp:bfsLayer
|
4
|